The management of refractory Crohn's disease
Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Rizzello, F. [verfasserIn] Gionchetti, P. [verfasserIn] Venturi, A. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Science, Ltd ; 2002 |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2002 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Alimentary pharmacology & therapeutics - Oxford : Blackwell Science, 1987, 16(2002), Seite 0 |
| Übergeordnetes Werk: |
volume:16 ; year:2002 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1046/j.1365-2036.16.s4.6.x |
|---|
| Katalog-ID: |
NLEJ242204481 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242204481 | ||
| 003 | DE-627 | ||
| 005 | 20230506180912.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2002 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1046/j.1365-2036.16.s4.6.x |2 doi | |
| 035 | |a (DE-627)NLEJ242204481 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Rizzello, F. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a The management of refractory Crohn's disease |
| 264 | 1 | |a Oxford, UK |b Blackwell Science, Ltd |c 2002 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy. | ||
| 533 | |d 2002 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2002|||||||||| | ||
| 700 | 1 | |a Gionchetti, P. |e verfasserin |4 aut | |
| 700 | 1 | |a Venturi, A. |e verfasserin |4 aut | |
| 700 | 1 | |a Morselli, C. |4 oth | |
| 700 | 1 | |a Campieri, M. |4 oth | |
| 773 | 0 | 8 | |i In |t Alimentary pharmacology & therapeutics |d Oxford : Blackwell Science, 1987 |g 16(2002), Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926529 |w (DE-600)2003094-0 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2002 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1046/j.1365-2036.16.s4.6.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2002 |h 0 | ||
| author_variant |
f r fr p g pg a v av |
|---|---|
| matchkey_str |
article:13652036:2002----::hmngmnorfatrc |
| hierarchy_sort_str |
2002 |
| publishDate |
2002 |
| allfields |
10.1046/j.1365-2036.16.s4.6.x doi (DE-627)NLEJ242204481 DE-627 ger DE-627 rakwb Rizzello, F. verfasserin aut The management of refractory Crohn's disease Oxford, UK Blackwell Science, Ltd 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Gionchetti, P. verfasserin aut Venturi, A. verfasserin aut Morselli, C. oth Campieri, M. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 pages:0 http://dx.doi.org/10.1046/j.1365-2036.16.s4.6.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 0 |
| spelling |
10.1046/j.1365-2036.16.s4.6.x doi (DE-627)NLEJ242204481 DE-627 ger DE-627 rakwb Rizzello, F. verfasserin aut The management of refractory Crohn's disease Oxford, UK Blackwell Science, Ltd 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Gionchetti, P. verfasserin aut Venturi, A. verfasserin aut Morselli, C. oth Campieri, M. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 pages:0 http://dx.doi.org/10.1046/j.1365-2036.16.s4.6.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 0 |
| allfields_unstemmed |
10.1046/j.1365-2036.16.s4.6.x doi (DE-627)NLEJ242204481 DE-627 ger DE-627 rakwb Rizzello, F. verfasserin aut The management of refractory Crohn's disease Oxford, UK Blackwell Science, Ltd 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Gionchetti, P. verfasserin aut Venturi, A. verfasserin aut Morselli, C. oth Campieri, M. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 pages:0 http://dx.doi.org/10.1046/j.1365-2036.16.s4.6.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 0 |
| allfieldsGer |
10.1046/j.1365-2036.16.s4.6.x doi (DE-627)NLEJ242204481 DE-627 ger DE-627 rakwb Rizzello, F. verfasserin aut The management of refractory Crohn's disease Oxford, UK Blackwell Science, Ltd 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Gionchetti, P. verfasserin aut Venturi, A. verfasserin aut Morselli, C. oth Campieri, M. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 pages:0 http://dx.doi.org/10.1046/j.1365-2036.16.s4.6.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 0 |
| allfieldsSound |
10.1046/j.1365-2036.16.s4.6.x doi (DE-627)NLEJ242204481 DE-627 ger DE-627 rakwb Rizzello, F. verfasserin aut The management of refractory Crohn's disease Oxford, UK Blackwell Science, Ltd 2002 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Gionchetti, P. verfasserin aut Venturi, A. verfasserin aut Morselli, C. oth Campieri, M. oth In Alimentary pharmacology & therapeutics Oxford : Blackwell Science, 1987 16(2002), Seite 0 Online-Ressource (DE-627)NLEJ243926529 (DE-600)2003094-0 1365-2036 nnns volume:16 year:2002 pages:0 http://dx.doi.org/10.1046/j.1365-2036.16.s4.6.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 16 2002 0 |
| source |
In Alimentary pharmacology & therapeutics 16(2002), Seite 0 volume:16 year:2002 pages:0 |
| sourceStr |
In Alimentary pharmacology & therapeutics 16(2002), Seite 0 volume:16 year:2002 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Alimentary pharmacology & therapeutics |
| authorswithroles_txt_mv |
Rizzello, F. @@aut@@ Gionchetti, P. @@aut@@ Venturi, A. @@aut@@ Morselli, C. @@oth@@ Campieri, M. @@oth@@ |
| publishDateDaySort_date |
2002-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926529 |
| id |
NLEJ242204481 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242204481</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506180912.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2002 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-2036.16.s4.6.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242204481</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rizzello, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The management of refractory Crohn's disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science, Ltd</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gionchetti, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Venturi, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morselli, C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Campieri, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Alimentary pharmacology & therapeutics</subfield><subfield code="d">Oxford : Blackwell Science, 1987</subfield><subfield code="g">16(2002), Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926529</subfield><subfield code="w">(DE-600)2003094-0</subfield><subfield code="x">1365-2036</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2002</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-2036.16.s4.6.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2002</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Rizzello, F. |
| spellingShingle |
Rizzello, F. The management of refractory Crohn's disease |
| authorStr |
Rizzello, F. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926529 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1365-2036 |
| topic_title |
The management of refractory Crohn's disease |
| publisher |
Blackwell Science, Ltd |
| publisherStr |
Blackwell Science, Ltd |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
c m cm m c mc |
| hierarchy_parent_title |
Alimentary pharmacology & therapeutics |
| hierarchy_parent_id |
NLEJ243926529 |
| hierarchy_top_title |
Alimentary pharmacology & therapeutics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926529 (DE-600)2003094-0 |
| title |
The management of refractory Crohn's disease |
| ctrlnum |
(DE-627)NLEJ242204481 |
| title_full |
The management of refractory Crohn's disease |
| author_sort |
Rizzello, F. |
| journal |
Alimentary pharmacology & therapeutics |
| journalStr |
Alimentary pharmacology & therapeutics |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2002 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Rizzello, F. Gionchetti, P. Venturi, A. |
| container_volume |
16 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Rizzello, F. |
| doi_str_mv |
10.1046/j.1365-2036.16.s4.6.x |
| author2-role |
verfasserin |
| title_sort |
the management of refractory crohn's disease |
| title_auth |
The management of refractory Crohn's disease |
| abstract |
Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy. |
| abstractGer |
Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy. |
| abstract_unstemmed |
Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| title_short |
The management of refractory Crohn's disease |
| url |
http://dx.doi.org/10.1046/j.1365-2036.16.s4.6.x |
| remote_bool |
true |
| author2 |
Gionchetti, P. Venturi, A. Morselli, C. Campieri, M. |
| author2Str |
Gionchetti, P. Venturi, A. Morselli, C. Campieri, M. |
| ppnlink |
NLEJ243926529 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1046/j.1365-2036.16.s4.6.x |
| up_date |
2024-07-06T01:12:21.999Z |
| _version_ |
1803790153945186305 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242204481</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506180912.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2002 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-2036.16.s4.6.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242204481</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Rizzello, F.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The management of refractory Crohn's disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science, Ltd</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Refractoriness to conventional therapy is a common and intriguing problem in Crohn's disease patients. At the present time there is no agreement on its definition and several mechanisms are involved in its determination. Immunosuppressors, such as azathioprine (AZA), 6-mercaptopurine (6MP) and methotrexate (MTX) are effective drugs for controlling the inflammatory process and avoid chronic glucocorticosteroid treatment and its related related side-effects. Recently, the introduction of tumour necrosis factor antibodies (infliximab) has dramatically changed the natural history of Crohn's disease and its therapeutic approach. Several studies have determined the efficacy, mechanisms and safety of infliximab. However, this molecular approach has also left several questions unanswered about the mechanisms of refractoriness, possible concomitant treatments and long-term safety and efficacy.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gionchetti, P.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Venturi, A.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morselli, C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Campieri, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Alimentary pharmacology & therapeutics</subfield><subfield code="d">Oxford : Blackwell Science, 1987</subfield><subfield code="g">16(2002), Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926529</subfield><subfield code="w">(DE-600)2003094-0</subfield><subfield code="x">1365-2036</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2002</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-2036.16.s4.6.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2002</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.398941 |